Prospective validation of a proteomic urine test for early and accurate prognosis of critical course complications in patients with SARS-CoV-2 infection

Prospective validation of a proteomic urine test for early and accurate prognosis of critical course complications in patients with SARS-CoV-2 infection - Crit-Cov-U

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00022495

Enrollment

1000

Registered

2020-08-25

Start date

2020-08-01

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

U07.9

Interventions

Group 1: Not applicable (observational study) Patients are screened for their urinary proteome and compared whether a proteome risk score is associated with the clinical severity of Covid-19 disease

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Covid-19 disease Ability for informed consent

Exclusion criteria

Exclusion criteria: Anuria

Design outcomes

Primary

Measure	Time frame
Predictive strength of a urine protein fragment pattern (proteomics) for the severity of Covid19 disease	—

Secondary

Measure	Time frame
Best time-point to use the urinary proteomic test for severity prediction of Covid-19 disease	—

Countries

Austria, France, Germany, Poland, Spain, Sweden

Contacts

Public ContactHeiko von der Leyen

Medizinische Hochschule HannoverHannover Clinical Trial Center

vonderLeyen.Heiko@mh-hannover.de+49 (0) 511 532 115-10

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026